Cargando…

Real-world adherence to toxicity management guidelines for immune checkpoint inhibitor-induced diabetes mellitus

OBJECTIVE: Immune checkpoint inhibitors(ICIs) have improved survival and are increasingly used for cancer. However, ICIs use may be limited by immune-related adverse events (irAEs), such as ICI-induced diabetes mellitus(ICI-DM). The objective of the present study was to characterize ICI-DM patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shen, Min, Chen, Doudou, Zhao, Ruiling, Zheng, Xuqin, Gu, Yong, Yang, Tao, Shi, Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405819/ https://www.ncbi.nlm.nih.gov/pubmed/37554766 http://dx.doi.org/10.3389/fendo.2023.1213225

Ejemplares similares

Growth differentiation factor-15/adiponectin ratio as a potential biomarker for metabolic syndrome in Han Chinese
por: Zheng, Shuai, et al.
Publicado: (2023)

Real-World Adherence to Toxicity Management Guidelines for Immune-Related Adverse Events
por: Teimouri, Arezou, et al.
Publicado: (2022)

Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus
por: Hilder, Robin, et al.
Publicado: (2023)

Association of subclass distribution of insulin antibody with glucose control in insulin-treated type 2 diabetes mellitus: a retrospective observational study
por: Chen, Shuang, et al.
Publicado: (2023)

Endocrine side effects of immune checkpoint inhibitors
por: Cardona, Zulma, et al.
Publicado: (2023)

Outcomes and toxicities of immune checkpoint inhibitors in colorectal cancer: a real‐world retrospective analysis
por: Zhou, Chengjing, et al.
Publicado: (2021)

Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study
por: Li, Na, et al.
Publicado: (2023)

Durability of glucose-lowering effect of dulaglutide in patients with type 2 diabetes mellitus: A real-world data study
por: Kim, Hwi Seung, et al.
Publicado: (2022)

Coexistence of Immune Checkpoint Inhibitor-Induced Autoimmune Diabetes and Pancreatitis
por: Zhang, Amy L., et al.
Publicado: (2021)

Thyroid-related adverse events induced by immune checkpoint inhibitors
por: Chera, Alexandra, et al.
Publicado: (2022)

Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM
por: Zhang, Wenjing, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management
por: Zhan, Ling, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
por: Di Molfetta, Sergio, et al.
Publicado: (2021)

Editorial: Immune checkpoint inhibitors in cancer: balancing the benefits with the side effects?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2023)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
por: She, Jianqing, et al.
Publicado: (2022)

Editorial: Decoding checkpoint inhibitor-induced endocrinopathies
por: Burnett, Deborah L., et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced hypothyroidism predicts treatment response in Japanese subjects
por: Iwamoto, Yuichiro, et al.
Publicado: (2023)

Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist’s Perspective
por: Song, Zhi-Hui, et al.
Publicado: (2022)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
por: Bol, Kalijn Fredrike, et al.
Publicado: (2019)

Real-world safety experience with immune checkpoint inhibitors in Saudi Arabia
por: Al Nuhait, Mohammed, et al.
Publicado: (2021)

Metabolic and Nutritional Disorders Following the Administration of Immune Checkpoint Inhibitors: A Pharmacovigilance Study
por: Zhai, Yinghong, et al.
Publicado: (2022)

Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task
por: Barnabei, Agnese, et al.
Publicado: (2022)

Editorial: Decoding checkpoint inhibitor-induced immune-related adverse events, volume II
por: Burnett, Deborah L., et al.
Publicado: (2023)

Predicting diabetic kidney disease for type 2 diabetes mellitus by machine learning in the real world: a multicenter retrospective study
por: Liu, Xiao zhu, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review
por: Hong, A Ram, et al.
Publicado: (2020)

Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea
por: Kim, Soo Young, et al.
Publicado: (2019)

Eligibility and Awareness Regarding Metabolic Surgery in Patients With Type 2 Diabetes Mellitus in the Real-World Clinical Setting; Estimate of Possible Diabetes Remission
por: Koliaki, Chrysi, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor Uptake in Real-World Patients With Malignant Pleural Mesothelioma
por: Kim, Roger Y., et al.
Publicado: (2021)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
por: Toribio-García, Irene, et al.
Publicado: (2023)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside
por: Wu, Linda, et al.
Publicado: (2021)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world
por: Xie, Diyang, et al.
Publicado: (2021)

Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study
por: Huang, Kuang-Hua, et al.
Publicado: (2022)

Immune checkpoint inhibitor– and phosphatidylinositol-3-kinase inhibitor–related diabetes induced by antineoplastic drugs: two case reports and a literature review
por: Gao, Yue, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011–2021
por: Zhang, Hongyi, et al.
Publicado: (2023)

Real-world evidence studies into treatment adherence, thresholds for intervention and disparities in treatment in people with type 2 diabetes in the UK
por: McGovern, Andrew, et al.
Publicado: (2016)

Adolopment of adult diabetes mellitus management guidelines for a Pakistani context: Methodology and challenges
por: Martins, Russell Seth, et al.
Publicado: (2023)

Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study
por: Lee, Hanna J., et al.
Publicado: (2023)

Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System
por: La, Jennifer, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_342atoj0v7mssfcbbebp4cf8rs